The board of directors of The United Laboratories International Holdings Limited announced that it was informed by China State Food and Drug Administration that the applications of the Group's insulin glargin bulk medicine and insulin glargin finished product have been approved with approval number of S20160010 and S20160009 respectively. The approved insulin glargin product is the specification of refilled pen-type injection. It is expected that the relevant insulin products will be launched to the market soon. Insulin glargin is a long-acting insulin analog of the third generation insulin products. In addition, the Group's four recombinant human insulin finished products of the second generation insulin (including the four specifications: N, R, 30R and 50R) have been launched to the market in 2011. After the approval of insulin glargin, the Group is the pharmaceutical enterprise of the second and third generation insulin products in China. Apart from the products mentioned above, the Group's insulin products in R&D also cover insulin aspart, insulin detemir, insulin degludec, etc. It is expected that the above products will be launched to the market gradually so that the Group's insulin pipeline will be enriched and will bring considerable return to the company and its shareholders in future.